Periorbital changes associated with prostaglandin analogs in Korean patients

Kim, Hee Weon; Choi, Youn Joo; Lee, Kyung Wha; Lee, Min Joung

doi:10.1186/s12886-017-0521-4

Cited by 19 publications

(15 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Besides, prostaglandin-associated periorbitopathy such as orbital fat atrophy has been described especially with Bimatoprost and may impact proptosis measures and the assessment of the severity of GO. 28–30…”

Section: Discussionmentioning

confidence: 99%

The effects of Rituximab on Graves’orbitopathy: A retrospective study of 14 patients

Eid¹,

Coste-Verdier²,

Longueville³

et al. 2019

European Journal of Ophthalmology

View full text Add to dashboard Cite

Purpose: Management of Graves’ ophthalmopathy remains challenging. Over the last decade, previous studies have shown promising results for Rituximab in the treatment of Graves’ ophthalmopathy. We present the response of 14 individuals with active moderate-to-severe Graves’ ophthalmopathy to Rituximab, representing one of the largest retrospective case series reported to date. Methods: Rituximab was administered intravenously, 1000 mg twice at a 2-week interval. The primary end point was a clinical activity score reduction (improvement by ⩾ 2 points or disease inactivation: clinical activity score < 3) at 24 weeks. Secondary end points included clinical activity score improved by ⩾ 2 points or inactivation of Graves’ ophthalmopathy at 12 weeks, improvement in each item of the clinical activity score, in proptosis, in severity disease by the total eye score and in diplopia according to the Gorman score. Results: A limited improvement in clinical activity score was observed (median improvement at 24 weeks by 1 point, p = 0.002, (5/14 patients, 35.7%). Disease inactivation occurred in 50% of patients (7/14 patients). At 12 weeks, clinical activity score improved by ⩾ 2 points in 2/14 patients (14.3%) and inactivation of Graves’ ophthalmopathy occurred in four patients (28.6%). Improvement in proptosis and total eye score was observed in 3/9 patients (33%) and in 4/14 patients (28.6%) at 24 weeks, respectively. Only one patient experienced moderate adverse event. Conclusion: Rituximab is a well-tolerated treatment with a good safety profile, but offered limited and partial improvement for active moderate-to-severe Graves’ ophthalmopathy with a long duration of disease.

show abstract

Section: Discussionmentioning

confidence: 99%

The effects of Rituximab on Graves’orbitopathy: A retrospective study of 14 patients

Eid¹,

Coste-Verdier²,

Longueville³

et al. 2019

European Journal of Ophthalmology

View full text Add to dashboard Cite

show abstract

“…PGF2α inhibits adipogenesis per se but does not affect lipolysis and hence has no impact on an already fully mature adipocyte (20). Not all glaucoma patients treated with PGF2α develop periorbital fat atrophy with an estimated incidence of 24.1% (24). Some patients with GO have predominantly fat excess whilst the others have muscle predominant disease (25).…”

Section: Discussionmentioning

confidence: 99%

Prostaglandin F2-Alpha Eye Drops (Bimatoprost) in Graves' Orbitopathy: A Randomized Controlled Double-Masked Crossover Trial (BIMA Trial)

Draman

Morris

Evans

et al. 2019

Thyroid

View full text Add to dashboard Cite

Background: Previous in vitro experiments have demonstrated that PGF2α reduced proliferation and adipogenesis in a murine cell line and human orbital fibroblasts derived from subjects with inactive Graves' orbitopathy (GO). The objective of this study was to determine if the PGF2α analogue Bimatoprost is effective at reducing proptosis in this population.Methods: A randomized controlled double-masked crossover trial was conducted in a single tertiary care academic medical center. Patients with longstanding, inactive GO but persistent proptosis (> 20 mm in at least one eye) were recruited. Allowing for a 15% dropout rate, 31 patients (26 females) were randomized in order to identify a treatment effect of 2.0 mm (p=0.05, two-sided paired t-test, power 0.88). Following informed consent, participants were randomized to receive Bimatoprost or placebo for three months after which they underwent a two-month washout, before switching to the opposite treatment. The primary outcome was the change in exophthalmometry readings over the two 3-month treatment periods.Results: The mean exophthalmometer at baseline was 23.6 (range 20.0-30.5) mm and the mean age was 55 (range 28-74) years. The median duration of GO was 7.6 (IQR 3.6-12.3) years. The majority were still suffering from diplopia (61.3%) with bilateral involvement (61.3%). Using multilevel modeling adjusted for baseline, period and carryover, Bimatoprost resulted in a -0.17 mm (reduction) exophthalmometry change (95% CI -0.67 to +0.32) p=0.490. Intraocular pressure was reduced -2.7 mmHg (95% CI -4.0 to -1.4) p=0.0070. One patient showed periorbital fat atrophy (PAP) on treatment which resolved on stopping treatment. Independent analysis of proptosis by

show abstract

“…They do have some local side effects, however, such as causing prostaglandin-associated periorbitopathy (PAP), including periorbital fat atrophy, enophthalmos, deepening of the upper eyelid sulcus (DUES), and upper eyelid ptosis [14–19]. The mechanism of the symptoms has not been clearly identified but is thought to be related to the effect of PGF 2α on adipocytes [20]. PAP has been reported to be more frequently associated with bimatoprost administration than with that of other PGF 2α analogs, such as latanoprost, travoprost, and tafluprost [21, 22].…”

Section: Introductionmentioning

confidence: 99%

Decreased orbital fat and enophthalmos due to bimatoprost: Quantitative analysis using magnetic resonance imaging

et al. 2019

View full text Add to dashboard Cite

We quantitatively determined the relation between the decrease in orbital fat and enophthalmos due to bimatoprost using magnetic resonance imaging (MRI). Nine orbits in nine patients were treated unilaterally with bimatoprost for glaucoma or ocular hypertension. The contralateral orbits were used as controls. The volumes of the orbital tissues and the enophthalmos were measured using MRI. The mean volumes on the treated and untreated sides were, respectively, 14.6 ± 2.1 and 17.0 ± 4.3 cm 3 for orbital fat ( P = 0.04) and 3.4 ± 0.5 and 3.3 ± 0.5 cm 3 for total extraocular muscles ( P = 0.85). The mean enophthalmos values were 14.7 ± 2.5 and 16.0 ± 2.3 mm on the treated and untreated sides, respectively ( P = 0.002). The data acquired by quantitatively measuring the volumes of orbital fat and enophthalmos on MRI showed that each might be reduced by bimatoprost administration. The enophthalmos could be caused by the bimatoprost-induced decrease in orbital fat.

show abstract

Periorbital changes associated with prostaglandin analogs in Korean patients

Cited by 19 publications

References 26 publications

The effects of Rituximab on Graves’orbitopathy: A retrospective study of 14 patients

The effects of Rituximab on Graves’orbitopathy: A retrospective study of 14 patients

Prostaglandin F2-Alpha Eye Drops (Bimatoprost) in Graves' Orbitopathy: A Randomized Controlled Double-Masked Crossover Trial (BIMA Trial)

Decreased orbital fat and enophthalmos due to bimatoprost: Quantitative analysis using magnetic resonance imaging

Contact Info

Product

Resources

About